Cargando…

Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma

PURPOSE: Limb-bud and heart (LBH) levels are correlated with adverse survival in several malignancies; however, their significance in hepatocellular carcinoma (HCC) remains unclear. The objective of this study was to determine the association between LBH status and clinical outcomes. METHODS: We sel...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiewei, Huang, Chuqiang, Chen, Keming, Li, Shuman, Zhang, Xinke, Cheng, Jun, Cai, Muyan, Xiao, Yongbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783013/
https://www.ncbi.nlm.nih.gov/pubmed/29403288
http://dx.doi.org/10.2147/OTT.S152953
_version_ 1783295227483652096
author Chen, Jiewei
Huang, Chuqiang
Chen, Keming
Li, Shuman
Zhang, Xinke
Cheng, Jun
Cai, Muyan
Xiao, Yongbo
author_facet Chen, Jiewei
Huang, Chuqiang
Chen, Keming
Li, Shuman
Zhang, Xinke
Cheng, Jun
Cai, Muyan
Xiao, Yongbo
author_sort Chen, Jiewei
collection PubMed
description PURPOSE: Limb-bud and heart (LBH) levels are correlated with adverse survival in several malignancies; however, their significance in hepatocellular carcinoma (HCC) remains unclear. The objective of this study was to determine the association between LBH status and clinical outcomes. METHODS: We selected 226 patients with HCC who were treated surgically between 2003 and 2010 at a single academic center. Immunohistochemistry (IHC) was used to detect the protein expression of LBH in HCC samples. Receiver operating characteristic (ROC) curve analysis, Spearman’s rank correlation, Kaplan–Meier plots, and the Cox proportional hazards regression model were used to analyze the data. RESULTS: A high expression of LBH was detected in 20 (8.8%) of 226 HCC samples. Correlation analysis demonstrated that LBH in HCC was significantly correlated with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels and clinical stages (P<0.05). In the Kaplan–Meier analysis, the mean survival time of patients with low levels of LBH was longer than that for those with high levels of LBH (P<0.05). The 3-year overall survival rate was 20% for patients with HCC and high levels of LBH versus 67% for patients with HCC and low levels of LBH. In the multivariate analysis, AST/ALT level, clinical stage, tumor relapse, and the level of LBH were the independent prognostic factors for overall survival (P<0.05). CONCLUSION: Overexpression of LBH might contribute to the development and progression of HCC. LBH could be a novel prognostic marker for HCC.
format Online
Article
Text
id pubmed-5783013
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57830132018-02-05 Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma Chen, Jiewei Huang, Chuqiang Chen, Keming Li, Shuman Zhang, Xinke Cheng, Jun Cai, Muyan Xiao, Yongbo Onco Targets Ther Original Research PURPOSE: Limb-bud and heart (LBH) levels are correlated with adverse survival in several malignancies; however, their significance in hepatocellular carcinoma (HCC) remains unclear. The objective of this study was to determine the association between LBH status and clinical outcomes. METHODS: We selected 226 patients with HCC who were treated surgically between 2003 and 2010 at a single academic center. Immunohistochemistry (IHC) was used to detect the protein expression of LBH in HCC samples. Receiver operating characteristic (ROC) curve analysis, Spearman’s rank correlation, Kaplan–Meier plots, and the Cox proportional hazards regression model were used to analyze the data. RESULTS: A high expression of LBH was detected in 20 (8.8%) of 226 HCC samples. Correlation analysis demonstrated that LBH in HCC was significantly correlated with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels and clinical stages (P<0.05). In the Kaplan–Meier analysis, the mean survival time of patients with low levels of LBH was longer than that for those with high levels of LBH (P<0.05). The 3-year overall survival rate was 20% for patients with HCC and high levels of LBH versus 67% for patients with HCC and low levels of LBH. In the multivariate analysis, AST/ALT level, clinical stage, tumor relapse, and the level of LBH were the independent prognostic factors for overall survival (P<0.05). CONCLUSION: Overexpression of LBH might contribute to the development and progression of HCC. LBH could be a novel prognostic marker for HCC. Dove Medical Press 2018-01-19 /pmc/articles/PMC5783013/ /pubmed/29403288 http://dx.doi.org/10.2147/OTT.S152953 Text en © 2018 Chen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Chen, Jiewei
Huang, Chuqiang
Chen, Keming
Li, Shuman
Zhang, Xinke
Cheng, Jun
Cai, Muyan
Xiao, Yongbo
Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma
title Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma
title_full Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma
title_fullStr Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma
title_full_unstemmed Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma
title_short Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma
title_sort overexpression of lbh is associated with poor prognosis in human hepatocellular carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783013/
https://www.ncbi.nlm.nih.gov/pubmed/29403288
http://dx.doi.org/10.2147/OTT.S152953
work_keys_str_mv AT chenjiewei overexpressionoflbhisassociatedwithpoorprognosisinhumanhepatocellularcarcinoma
AT huangchuqiang overexpressionoflbhisassociatedwithpoorprognosisinhumanhepatocellularcarcinoma
AT chenkeming overexpressionoflbhisassociatedwithpoorprognosisinhumanhepatocellularcarcinoma
AT lishuman overexpressionoflbhisassociatedwithpoorprognosisinhumanhepatocellularcarcinoma
AT zhangxinke overexpressionoflbhisassociatedwithpoorprognosisinhumanhepatocellularcarcinoma
AT chengjun overexpressionoflbhisassociatedwithpoorprognosisinhumanhepatocellularcarcinoma
AT caimuyan overexpressionoflbhisassociatedwithpoorprognosisinhumanhepatocellularcarcinoma
AT xiaoyongbo overexpressionoflbhisassociatedwithpoorprognosisinhumanhepatocellularcarcinoma